First Tracks Biotherapeutics (TRAX)

First Tracks Biotherapeutics (TRAX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.2B; returns 1 day +2.1%, 1 week +27.8%.

First Tracks Biotherapeutics (TRAX) is a clinical-stage biotechnology company that launched as an independent entity in April 2026 following a spin-off from AnaptysBio (ANAB). The company is focused on developing novel antibody therapeutics for autoimmune and inflammatory diseases.

Groups TRAX belongs to

• Biotechnology
• Clinical Stage Biotech
• Recent IPOs
• Autoimmune Diseases
• Antibody Therapeutics
• Biopharmaceutical
• Clinical Stage
• Healthcare
• Chronic Inflammatory Diseases
• R&D

TRAX financial model: income statement, cash flow and balance sheet